Introduction
The prevalence of diabetes mellitus in the general population is 4-7%, 1 and 32-44% in patients hospitalized for acute heart failure (AHF).
2 -5 Different underlying pathophysiological processes including inflammation and fibrosis may be present among patients with diabetes compared with those without diabetes. 6, 7 These differences in pathophysiology may also be seen between patients with and without diabetes who have heart failure (HF); 8, 9 however, evidence to support this is limited. Network analysis is an analytical technique used to gain insights into a biological system by predicting how multiple genes or proteins associate together. This analytical technique has been extensively used in ageing and cancer studies 10, 11 to gain greater insights into underlying disease mechanisms. Network analyses of blood biomarkers have been previously used to explore pathophysiological mechanisms in HF. 12, 13 Using network analysis, we can explore whether the underlying pathophysiological mechanisms among patients with and without diabetes are different in the setting of AHF. Traditionally, individual biomarkers would be correlated with clinical characteristics and outcomes in an attempt to gain an understanding of a disease; however, multiple mechanisms are likely to be active among patients with AHF.
14 Network analysis allows for multiple biomarkers-across a spectrum of pathophysiological domains-to be assessed for correlations simultaneously, leading to greater insights into the pathophysiology of disease states. Using an extensive set of biomarkers measured in patients with and without diabetes admitted for AHF, this study aimed to evaluate (i) the differences in biomarker levels and (ii) the patterns of inter-biomarker correlations using network analysis.
Methods

Study design and procedures
The Placebo-Controlled Randomized Study of the Selective A 1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) trial, a multicentre, randomized, double-blind, placebo-controlled trial with neutral results, enrolled 2033 adult patients hospitalized for AHF. 15 The main results of the study have been published previously. 15, 16 Key inclusion criteria included: persistent dyspnoea at rest or with minimal activity, impaired renal function (an estimated creatinine clearance of 20-80 mL/min with the use of the Cockcroft − Gault equation), a B-type natriuretic peptide (BNP) level of 500 pg/mL or more, or an N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of 2000 pg/mL or more, ongoing intravenous loop-diuretic therapy, and enrolment within 24 h after admission. All patients provided informed consent for the study including assessment of biomarkers. The study was conducted in compliance with the Declaration of Helsinki and was approved by all local Ethics Committees.
All routine laboratory values were assessed daily until discharge or Day 6 (or discharge if earlier), and on Days 7 and 14, as specified by the main study protocol. Additional biomarkers used in the present analysis were measured during baseline assessment. Full details of the biomarkers are described elsewhere. 17 (San Diego, CA, USA) in available frozen serum samples collected from each patient during baseline assessment. Galectin-3, myeloperoxidase and neutrophil gelatinase-associated lipocalin (NGAL) were measured using sandwich enzyme-linked immunosorbent assays (ELISAs) on a microtitre plate; angiogenin and C-reactive protein (CRP) were measured using competitive ELISAs on a Luminex ® platform; D-dimer, endothelial cell-selective adhesion molecule (ESAM), growth differentiation factor 15 (GDF-15), lymphotoxin beta receptor (LTBR), mesothelin, neuropilin, N-terminal pro C-type natriuretic peptide (NT-proCNP), osteopontin, procalcitonin (PCT), pentraxin-3, periostin, polymeric immunoglobulin receptor (PIGR), pro-adrenomedullin (proADM), prosaposin B (PSAP-B), receptor for advanced glycation end products (RAGE), soluble ST2, syndecan-1, tumour necrosis factor alpha receptor 1 (TNFR-1a), tumour necrosis factor receptor superfamily (TROY), vascular endothelial growth factor receptor 1 (VEGFR1), and WAP four-disulphide core domain protein HE4 (WAP4C) were measured using sandwich ELISAs on a Luminex ® platform. Immunoassays for PCT, proADM, galectin-3, and ST2 were developed by Alere. These research assays have not been standardized to the commercialized assays used in research or in clinical use and the extent to which each Alere assay correlates with the commercial assay is not fully characterized. Five additional biomarkers, namely interleukin-6, endothelin-1, kidney injury molecule-1 (KIM-1), cardiac troponin-I, and BNP were measured using a highly sensitive single molecule counting (SMC™) technology (RUO, Erenna ® Immunoassay System, Singulex Inc., Alameda, CA, USA). Glomerular filtration rate (GFR) was estimated using the simplified Modification of Diet in Renal Disease equation. Biomarker details are presented in the Supplementary material online, Table S1 . In addition to these biomarkers, we used baseline sodium, potassium, chloride, creatinine, urea, uric acid, total cholesterol, triglycerides, red blood cell count, haematocrit, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) in our network analyses. Approximately 250 L of EDTA plasma was used to measure the 48 biomarkers. As this was a hypothesis-generating analysis, we used all available biomarkers and routinely measured clinical biomarkers in our analysis.
Study population
The primary study population comprised 922 patients with diabetes and 1111 without diabetes. Biomarker data were available for 808 HF patients with diabetes and for 970 HF patients without diabetes. Baseline data on patients with and without biomarkers have been previously reported. 17 The definition of diabetes was ascertained through the electronic case report form and was based on patient-reported history of diabetes and use of anti-diabetic drugs. Data on the type of diabetes (i.e. type 1 vs. type 2) or the degree of glycaemic control (through glycated haemoglobin) were not collected.
Statistical analyses
Continuous variables are presented as mean ± standard deviation or median (interquartile range) for normally and non-normally distributed values, respectively. Student's t-tests and Wilcoxon tests were used to compare groups, as appropriate. A two-sided P-value <0.05 was considered statistically significant. To assess for significant differences in biomarker levels after adjustment for co-morbidities and medication use in patients with and without diabetes, we conducted a multivariable linear regression analysis in which each biomarker was entered as a dependent variable and diabetes and potential confounders [age, sex, ischaemic heart disease, peripheral vascular disease, estimated glomerular filtration rate, and angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) use] were included as independent variables. Principal component analysis (PCA) was performed to correct for multiple comparisons using biomarker measurements from AHF patients with and without diabetes as categorical variables.
11 -13 PCA is often used in -omics-based studies, where there is a natural correlation between markers reflective of the similar underlying pathophysiological processes, 18 and PCA-based correction for multiple comparisons has been suggested to be more effective than Bonferroni correction. 18, 19 PCA has been previously successfully used in correcting for multiple comparisons in pairwise correlations in other disease states.
11 A total of 37 principal components cumulatively explained >95% of the variation observed in the dataset when comparing both groups. The corrected significance level for multiple testing was thus set at P < 0.05/37, equating to an adjusted P-value cut-off of 0.001351. Next, a Spearman's rank correlation coefficient was calculated for each possible biomarker pair in the cohort of patients with diabetes and the procedure was repeated for patients without diabetes. This resulted in two sets of R values with associated P-values for both groups. To adjust for multiple testing, only those correlations passing the adjusted P-value cut-off calculated from the PCA were deemed statistically significant and subsequently retained. These significant correlation coefficients were then graphically displayed as heatmaps to reveal how biomarkers within patients with and without diabetes clustered together. Network analyses were then performed to analyse the cumulative associations between biomarkers in patients with and without diabetes. To better position the global associations of these biomarker interactions, biomarker data together with statistical data pertaining to each group of patients were utilized in a network analysis. Results of network analysis derived from patients with and without diabetes are shown in Figures 1 and 2 , respectively. The network analysis graphically represents two major findings: (i) whether biomarkers are correlated (i.e. how closely the levels of two biomarkers rise and fall-the strength of each biomarker-biomarker correlation is graphically represented by the thickness of the line connecting the biomarkers); and (ii) how biomarkers correlate [i.e. how closely the levels of biomarkers correlate with multiple neighbouring biomarkers-how closely a biomarker clusters with its neighbour is graphically represented by the size of the circle (or hub)]. We also assessed the correlation between individual biomarkers and routine clinical variables including height, weight, blood pressure, respiratory rate, pulse, and left ventricular ejection fraction (LVEF). The correlation coefficients were plotted as a correlogram.
Statistical analyses were performed using the STATA (version 11.0, STATA Corp., College Station, TX, USA), R (version 2.15.1, R Foundation for Statistical Computing, Vienna, Austria) software, and SPSS (IBM SPSS Statistics for Windows, Version 22.0, IBM Corp., Armonk, NY, USA).
Results
Baseline demographic and clinical characteristics
Compared with patients without diabetes, those with diabetes had a higher prevalence of ischaemic heart disease, previous coronary intervention, renal dysfunction, body mass index, and other traditional coronary risk factors ( 
Biomarker expression
Patients with diabetes had consistently higher levels of inflammatory biomarkers compared with patients without diabetes, which included PIGR, RAGE, TNFR-1a, GDF-15, WAP4C ( Figure 3 , Table 2 ). The remodelling specific biomarkers (syndecan-1 and galectin-3), atherosclerosis markers (LTBR), lipids (triglycerides, total cholesterol), and renal markers [creatinine, blood urea nitrogen (BUN), NGAL, KIM-1] were significantly higher in patients with diabetes compared with those without diabetes. The remodelling marker periostin, cardiomyocyte stretch marker BNP, and thrombosis marker D-dimer were higher in patients without diabetes compared with patients with diabetes. After adjustment for age, sex, clinical covariates, and ACEi/ARB use, pentraxin-3, TNFR-1a, D-dimer, periostin, BNP, VEGFR, angiogenin, LTBR, NGAL, and KIM-1 were significantly different between patients with and without diabetes (adjusted P-value <0.05; Supplementary material online, Table S2 ).
Biomarker correlation with network analysis
Statistically significant biomarker correlations that survived multiple testing within the diabetes and non-diabetes groups are depicted as heatmaps (Supplementary material online, Figures  S1 and S2, and Tables S3 and S4, respectively). The strongest inter-biomarker correlation observed in patients with diabetes involved the association between glucose and triglycerides ( Figure 1 ; Supplementary material online, Table S3 ). Furthermore, a renal-potassium-glucose correlation emerged among patients with diabetes; potassium was strongly correlated with glucose, creatinine, and NGAL ( Figure 1 ). Periostin had the largest hub, suggesting that this biomarker strongly clusters around the neighbouring inflammatory biomarkers CRP and IL-6. Among patients without diabetes, these associations were not seen ( Figure 2) ; however, BUN is strongly correlated with troponin and BNP associates with AST. Furthermore, among patients without diabetes, the angiogenesis marker angiogenin appeared to strongly cluster with BUN and another angiogenesis marker (TROY). Periostin does not appear to significantly associate or cluster with other biomarkers among patients without diabetes. Among the association between biomarkers and clinical variables, the most significant correlations occurred with LVEF and the biomarkers. Among patients with diabetes, LVEF was strongly associated with D-dimer, RAGE, and IL-6. Among patients without diabetes, the strongest clinical and biomarker correlations were seen with LVEF and D-dimer, NT-proCNP and BNP (Supplementary material online, Figures S3 and S4 ).
Discussion
To our knowledge this is the first network analysis to identify correlations and clusters of associations using an extensive panel of biomarkers in patients with and without diabetes in AHF. The three main findings of the present study were: (i) there The colour of the circular hubs (biomarkers) and lines (associations) represent the strength of the clustering coefficient and strength of inter-biomarker correlations, respectively; these range from blue, strongest, to orange, weakest. Of all statistically significant associations depicted, glucose and triglycerides are the most strongly correlated with each other, reflected by the thickness of the line. Periostin has the largest hub, reflecting strong additive correlations with C-reactive protein and interleukin-6. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; CRP, C-reactive protein; cTnI, cardiac troponin-I; ESAM, endothelial cell-selective adhesion molecule; GDF-15, growth differentiation factor 15; IL-6, interleukin-6; KIM-1, kidney injury molecule-1; MPO, myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin; NT-proCNP, N-terminal pro-C-type natriuretic peptide; proADM, pro-adrenomedullin; PSAP-B, prosaposin B; RAGE, receptor for advanced glycation end products; RBC, red blood cells; TNFR-1a, tumour necrosis factor alpha receptor 1; TROY, tumour necrosis factor receptor superfamily; WAP4C, WAP four-disulphide core domain protein HE4; WBC, white blood cells. The colour of the circular hubs (biomarkers) and lines (associations) represent the strength of the clustering coefficient and strength of inter-biomarker correlations, respectively; these range from blue, strongest, to orange, weakest. While no one dominant association was seen, the strongest correlation appears to be with aspartate aminotransferase and B-type natriuretic peptide. Angiogenin has the largest hub, reflecting strong additive correlation with blood urea nitrogen and tumour necrosis factor receptor superfamily. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CRP, C-reactive protein; cTnI, cardiac troponin-I; ESAM, endothelial cell-selective adhesion molecule; ET-1, endothelin-1; GDF-15, growth differentiation factor 15; KIM-1, kidney injury molecule-1; LTBR, lymphotoxin beta receptor; MPO, myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin; NT-proCNP, N-terminal pro-C-type natriuretic peptide; PIGR, polymeric immunoglobulin receptor; proADM, pro-adrenomedullin; PSAP-B, prosaposin B; RAGE, receptor for advanced glycation end products; RBC, red blood cells; sST2, soluble ST2; TNFR-1a, tumour necrosis factor alpha receptor 1; TROY, tumour necrosis factor receptor superfamily; VEGFR-1, vascular endothelial growth factor receptor 1; WAP4C, WAP four-disulphide core domain protein HE4; WBC, white blood cells. 
Differences in biomarker profiles
The association of diabetes, renal disease, and inflammation in humans has been described. 6, 7 Our results expand on these findings by demonstrating that even after multivariable adjustment the inflammatory marker TNFR-1a and renal markers (KIM-1, NGAL) were significantly higher in patients with diabetes compared with those without diabetes. Periostin was significantly lower in patients with diabetes even after multivariable adjustment. Periostin knockout models are associated with increased cardiac and valvular fibrosis. 20 Treatment with periostin in cardiac infarction models results in improvement in cardiac contractility and ventricular remodelling. 21 Lower periostin levels may suggest a reduced ability to undergo adaptive ventricular remodelling among patients with diabetes compared with patients without diabetes. In previous rat studies of diabetic cardiomyopathy, myocardial expression of periostin was higher. 22 The finding of lower periostin in our study may reflect differences in location of periostin measurement (serum vs. myocardium) or clinical state (acute vs. chronic HF). Overall, the significant differences in biomarker levels across a range of pathophysiological pathways provide empiric clues that different disease mechanisms may be present in patients with and without diabetes and AHF.
Our analysis revealed a higher BNP among patients without diabetes even after multivariable adjustment. While some reports have suggested a higher BNP associated with diabetes, 23 other large population studies and clinical trials have demonstrated lower BNP levels among patients with diabetes and HF. 3, 4 The lower BNP seen among patients with diabetes and HF likely reflects the higher incidence of obesity, which is known to associate with lower natriuretic peptide levels.
24
Correlation and clustering of biomarkers
Another important finding of the present study was that periostin clustered around established markers of fibrosis and inflammation (CRP and IL-6) in patients with diabetes. Our results extend upon work from existing experimental models. In diabetic rats, compared with controls, periostin is closely associated with ventricular fibrosis and adverse cardiac remodelling. 22 The use of valsartan in diabetic rats significantly improved ventricular remodelling and markers of fibrosis by possibly targeting the periostin pathway. 22 Our findings suggest that in patients with AHF, the mechanisms of cardiac remodelling, fibrosis, and inflammation are closely related; these findings were not observed in patients without diabetes. failure. Percentage change calculated by subtracting the median value of the baseline biomarker in patients with diabetes mellitus from the median value of the baseline biomarker in patients without diabetes mellitus and dividing the results by the median value of the biomarker with diabetics. * denotes statistically significant levels between diabetic and non-diabetic levels (P < 0.05). ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CRP, C-reactive protein; ESAM, endothelial cell-selective adhesion molecule; ET-1 endothelin-1; GDF-15, growth differentiation factor 15; IL-6, interleukin-6; KIM-1, kidney injury molecule-1; LTBR, lymphotoxin beta receptor; NGAL, neutrophil gelatinase-associated lipocalin; NT-proCNP, N-terminal pro-C-type natriuretic peptide; PCT, procalcitonin; PIGR, polymeric immunoglobulin receptor; proADM, pro-adrenomedullin; PSAP-B, prosaposin B; RAGE, receptor for advanced glycation end products; RBC, red blood cells; sST2, soluble ST2; TNFR-1a, tumour necrosis factor alpha receptor 1; VEGFR, vascular endothelial growth factor receptor; WAP4C, WAP four-disulphide core domain protein HE4; WBC, white blood cells.
Such analyses of blood biomarkers have been used to examine the pathophysiological mechanisms in patients with AHF 12 and among patients with HF with reduced and preserved ejection fraction. and acute inflammation. Periostin did not cluster around other inflammatory markers that were elevated among patients with diabetes, including RAGE and GDF-15. While all of these biomarkers act through the inflammatory cascade in some capacity, their different mechanisms of action are likely reflected in the lack of clustering seen between these proteins. 7, 21 The role of the periostin pathway and inflammation among patients with diabetes and HF warrants further evaluation. In addition to the periostin clustering, a renal-potassiumglucose correlation was present among patients with diabetes. This result suggests that potassium levels among patients with diabetes are more sensitive to changes in renal function. One potential explanation may relate to baseline medications; however, patients with diabetes were only slightly more likely to be on ACEi/ARB compared with patients without diabetes (78% vs. 74%; P = 0.03; Table 1 ) and were equally likely to be on mineralocorticoid receptor antagonists (42% vs. 46%; P = 0.1; Table 1 ). A history of diabetes has been shown to be an independent predictor of hyperkalaemia among patients with and without HF. 26 Our results extend on previous analyses suggesting that among patients with diabetes, potassium and glucose levels are correlated through insulin-mediated regulation, and this correlation is significantly influenced by insulin resistance and kidney disease. 27 Our findings have clinical implications: hyperkalaemia among patients with AHF may portend a worse prognosis; 26 clinicians need to aggressively monitor renal function and optimize potassium levels among patients with diabetes.
Among patients without diabetes, a cardiac stretch-hepatic relationship was seen as BNP correlated strongly with AST. Abnormal liver enzymes in patients admitted with AHF are correlated with worse prognosis; 28 our results suggest that changes in liver enzymes among patients with diabetes may be more sensitive to volume status and changes in cardiomyocyte stretch as reflected by BNP.
The network analysis results were further supported by the association of biomarkers and clinical data. The inflammatory molecules RAGE and IL-6 were the most strongly correlated with LVEF in patients with diabetes while NT-proCNP and BNP were the most strongly correlated with LVEF in patients without diabetes. These results suggest that inflammation and oxidation may be a dominant contributor to myocardial function among diabetics in AHF, while cardiomyocyte stretch may be a major contributor to myocardial function among patients without diabetes.
Clinical implications and future direction
Our results suggest that among patients with and without diabetes in AHF different underlying mechanisms of disease may exist. Periostin may be playing a central role in the pathogenesis of HF among patients with diabetes, and therapies targeting the periostin pathway may represent a novel treatment strategy. 21, 22, 25 Therapies that modulate the periostin pathway are being explored in cardiac models of HF and myocardial infarction. 29 Valsartan has demonstrated improvements in ventricular remodelling in diabetic rats potentially through the periostin pathway. 22 It is unclear whether ACEi target the periostin pathway. While there are no direct head to head comparisons of ACEi and ARBs in patients with diabetes and HF, comparative analyses have suggested that ARBs may be superior to ACEi in the setting of diabetic nephropathy. 30 Studies evaluating strategies that target the periostin pathway, with ARBs or other therapies, may represent a future direction of research among patients with diabetes and HF. In addition to cardiac disease, periostin plays a significant role in the mineralization of bone . 31 which has significant implications for osteoporosis development among patients with diabetes. 32 Further evaluation of bone morphogenetic protein-1 and lysyl oxidase activity, which are associated with periostin function, would be required to clarify the role of the periostin pathway in patients with diabetes and HF. 31 Furthermore, given the renal-potassium-glucose correlation seen in our analysis, strategies to optimize potassium may represent a strategy to improve outcomes among patients with diabetes and will need to be evaluated in prospective studies.
Strengths and limitations
This study is affected by the limitations of post hoc analyses, necessitating cautious interpretation. PROTECT had no specific design to warrant sufficient power for analyses of the diabetic subgroup. Information on anti-inflammatory medications was also not available. In addition, while patient medications may potentially affect biomarker levels, we did not adjust for this given the more descriptive nature of this analysis. In our study, we have used network analysis as a way to determine the underlying pathophysiological mechanisms and this method has been utilized in a variety of other analyses.
11 -13 While co-morbidities and medications differed among patients with and without diabetes, these were not adjusted for in the clustering analysis as the intent of our analysis was to reflect the overall subgroups of patients with and without diabetes. Type of diabetes (i.e. type 1 vs. type 2), degree of glycaemic control (through glycated haemoglobin), or duration of diabetes may potentially influence our results but were not collected in the PROTECT trial. Our findings are predominantly hypothesis generating; however, the conservative P-values used in our principal component analysis ensure a statistically more robust result.
Conclusion
Using network analyses, among AHF patients with and without diabetes, our findings suggest that cardiac remodelling, inflammation, and fibrosis-as reflected by the clustering of periostin, CRP, and IL-6-are closely associated among patients with diabetes. Furthermore, renal function, potassium levels, and glucose are closely correlated among patients with diabetes. These findings were not seen in patients without diabetes. Our study suggests that different pathophysiological pathways may be active among AHF patients with and without diabetes. Further research will be needed to explore these results.
Supplementary Information
Additional Supporting Information may be found in the online version of this article: Table S1 . Assay details and overview of measurements within assay range, per biomarker. Table S2 . Biomarkers with significant mean difference between patients with and without diabetes after multivariable adjustment. Figure S1 . Correlation heatmap of biomarker measurements of patients with acute heart failure and diabetes mellitus. Figure S2 . Correlation heatmap of biomarker measurements of patients with acute heart failure without diabetes mellitus. Figure S3 . Correlation between biomarkers and clinical variables in patients with diabetes. Figure S4 . Correlation between biomarkers and clinical variables in patients without diabetes.
